Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Expanded Access
Expanded Access
Approved
- Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
- No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
- Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
- Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
Contacts and Locations
Study Locations
-
-
-
Villejuif, France
-
-
-
-
Lower Saxony
-
Hannover, Lower Saxony, Germany
-
-
-
-
Auckland
-
Grafton, Auckland, New Zealand
-
-
-
-
-
Barcelona, Spain
-
-
-
-
California
-
San Francisco, California, United States
-
-
Indiana
-
Indianapolis, Indiana, United States
-
-
Kansas
-
Kansas City, Kansas, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Michigan
-
Ann Arbor, Michigan, United States
-
-
Minnesota
-
Rochester, Minnesota, United States
-
-
New York
-
New York, New York, United States, 10016
-
New York, New York, United States, 10032
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with evidence of chronic HCV (all genotypes) documented pretransplantation
- HCV RNA ≥ 10,000 IU/mL at screening
- Absence of organ rejection as documented by post transplant liver biopsy taken no more than 12 months prior to baseline/Day 1 visit
- Liver transplant ≥ 6 months and ≤ 12 years prior to screening
- Naive to all nucleotide/nucleoside treatments for chronic HCV infection
Exclusion Criteria:
- Multiorgan transplant that includes heart or lung recipient
- Subjects with de novo or recurrent Hepatocellular Carcinoma(HCC) post transplant
- Current use of corticosteroids at any dose > 5mg of prednisone/day (or equivalent dose of corticosteroid)
- Infection with hepatitis B virus (HBV) or HIV at screening
- Current, uncontrolled ascites, variceal hemorrhage, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome, or other signs of decompensated cirrhosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SOF+RBV
Participants will receive sofosbuvir+RBV for 24 weeks.
|
Sofosbuvir 400 mg tablet administered orally once daily
Other Names:
Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
Time Frame: Posttreatment Week 12
|
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, < 25 IU/mL) 12 weeks following the last dose of study drug.
|
Posttreatment Week 12
|
|
Percentage of Participants Who Discontinue Study Drug Due to an Adverse Event
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Sustained Virologic Response (SVR) at 4, 24, and 48 Weeks After Discontinuation of Therapy (SVR4, SVR24, and SVR48)
Time Frame: Posttreatment Weeks 4, 24, and 48
|
SVR4, SVR 24, and SVR 48 were defined as HCV RNA < LLOQ 4, 24, and 48 weeks following the last dose of study drug, respectively.
|
Posttreatment Weeks 4, 24, and 48
|
|
Percentage of Participants With HCV RNA < LLOQ at Weeks 12 and 24
Time Frame: Weeks 12 and 24
|
Weeks 12 and 24
|
|
|
HCV RNA and Change From Baseline at Weeks 2, 4, and 8
Time Frame: Baseline; Weeks 2, 4, and 8
|
Baseline; Weeks 2, 4, and 8
|
|
|
Percentage of Participants With Virologic Failure
Time Frame: Up to Posttreatment Week 24
|
Virologic failure was defined as on-treatment virologic failure or virologic relapse.
|
Up to Posttreatment Week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Jill M. Denning, MA, Gilead Sciences
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Disease Attributes
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis, Chronic
- Recurrence
- Hepatitis C, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Sofosbuvir
- Ribavirin
Other Study ID Numbers
Other Study ID Numbers
- GS-US-334-0126
- 2012-002417-19 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.